Adenosine A2AR agonist blocks mesenteric lymphatic epithelium, adipose tissue and Treg cells links of metabolic dysfunction-associated steatotic liver disease mice
Molecular and Cellular Endocrinology · 2025-12 · 610 · 112667
DOI: 10.1016/j.mce.2025.112667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2025-12. Verfasst von Tzu-Hao Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; School of M…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Adenosine A2 Receptor Agonists, Adenosine, Adipose Tissue. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Recent studies in diet-induced obese mice indicate crosstalk among mesentery, spleen, serum, and liver metabolites. Observations include decreased expression of the adenosine A2A receptor (A2AR), mesenteric lymphatic hyperpermeability, and reduced Treg cell populations in splenic and adipose tissues in metabolic dysfunction-associated steatotic liver disease (MASLD). This study aims to investigate the mechanisms and effects of a four-week treatment with the A2AR agonist CGS21680 in mice on a high-fat, high-sucrose diet-induced MASLD. In MASLD mice, reduced levels of mesenteric A2AR and the lymphatic epithelial marker LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) are associated with decreased Treg and M2 phenotype markers, alongside increased permeability markers/permeability of mesenteric lymphatic epithelium. Furthermore, elevated levels of pro-inflammatory cytokines IL-6 and TNFα were observed in serum and tissue homogenates, correlating with reduced splenic Treg cell populations and increased inflammation and fibrosis in mesenteric and hepatic tissues. Chronic treatment with CGS21680 significantly reversed these pathological changes. Additionally, co-incubation of splenic Treg cells with CGS21680 mitigated apoptosis, cellular injury, and leakage in SVEC monolayers, thereby preserving their integrity. This treatment also led to reduced cytokine release and promoted a shift towards an M2 phenotype in RAW 264.7 macrophages. Overall, the A2AR agonist CGS21680 shows promise as a therapeutic agent to inhibit both adipose tissue inflammation and hepatic inflammation/fibrosis by disrupting pathogenic links between adipose tissue, mesenteric lymphatics, and splenic Treg cells in MASLD mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; School o…
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Family Medicine, Taipei…
- Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
- Genomics Research Center, Academia Sinica, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Bei-Hu Branch, Taipei, Taiwan.
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Division of Allergy, Immunolog…
Förderung
- National Yang Ming Chiao Tung University
- Taipei Veterans General Hospital
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Li, T. H., Yeh, H. Y., Lin, S. W., Huang, Y. S., Zhuo, Z. W., Ma, C. C., Hsu, T. L., Wu, W. K., Tsai, H. C., Shen, H. C., Su, C. W., Yang, Y. Y., Lin, H. C., & Hou, M. C. (2025). Adenosine A2AR agonist blocks mesenteric lymphatic epithelium, adipose tissue and Treg cells links of metabolic dysfunction-associated steatotic liver disease mice. Molecular and Cellular Endocrinology, 610, 112667. https://doi.org/10.1016/j.mce.2025.112667
Vancouver
Li TH, Yeh HY, Lin SW, Huang YS, Zhuo ZW, Ma CC, et al. Adenosine A2AR agonist blocks mesenteric lymphatic epithelium, adipose tissue and Treg cells links of metabolic dysfunction-associated steatotic liver disease mice. Molecular and Cellular Endocrinology. 2025;610:112667. doi:10.1016/j.mce.2025.112667
BibTeX
@article{Li2025,
author = {Li, Tzu-Hao and Yeh, Hsiao-Yun and Lin, Shang-Wei and Huang, Yu-Shin and Zhuo, Zhen-Wei and Ma, Chia-Chen and Hsu, Tsui-Ling and Wu, Wei-Kai and Tsai, Hung-Cheng and Shen, Hsiao-Chin and Su, Chien-Wei and Yang, Ying-Ying and Lin, Han-Chieh and Hou, Ming-Chih},
title = {Adenosine A2AR agonist blocks mesenteric lymphatic epithelium, adipose tissue and Treg cells links of metabolic dysfunction-associated steatotic liver disease mice},
journal = {Molecular and Cellular Endocrinology},
year = {2025},
volume = {610},
pages = {112667},
doi = {10.1016/j.mce.2025.112667}
}
EUVIMED